Impact of drug alteration to maintain rhythm control in paroxysmal Atrial fibrillation

Subanalysis From J-RHYTHM Study

Ayaka Endo, Shun Kosaka, Shinya Suzuki, Hirotsugu Atarashi, Shiro Kamakura, Masayuki Sakurai, Haruaki Nakaya, Masahiko Fukatani, Hideo Mitamura, Tsutomu Yamazaki, Takeshi Yamashita, Satoshi Ogawa

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: The Japanese Rhythm Management Trial for Atrial Fibrillation (J-RHYTHM) study showed rhythm control was associated with fewer changes in the assigned treatment strategy compared to rate control in atrial fibrillation (AF). The aim was to describe how antiarrhythmics (AAs) were altered in the rhythm control arm and whether altering AAs would impact long-term outcomes. Methods and Results: Of 390 enrolled patients, 23.5% altered their AAs (drug alteration [DA] group). The hard endpoint (HE) was defined as a composite of death, stroke, embolism, major bleeding or heart failure hospitalization; soft endpoint (SE) was defined physical/psychological disability requiring alteration of treatment strategy. The patients were followed for 1.7 years. No significant difference was noted in the occurrence of HE (4.0% vs 6.5%, P=0.31), but DA-group patients had higher rates of SE (9.3% vs 18.4%, P=0.017) compared to single AA patients. The DA group was also associated with the occurrence of SE after adjustment (HR 1.90, P=0.042). When the DA group was subdivided according to the use of class III drugs or change of drugs between classes, there were no differences in outcomes. Conclusions: The need to change AA was associated with physical/psychological disabilities that seemed not to be relieved simply by changing AAs, and this should be considered as a marker for refractory paroxysmal AF requiring other strategies.

Original languageEnglish
Pages (from-to)870-875
Number of pages6
JournalCirculation Journal
Volume74
Issue number5
DOIs
Publication statusPublished - 2010

Fingerprint

Atrial Fibrillation
Pharmaceutical Preparations
Psychology
Anti-Arrhythmia Agents
Embolism
Hospitalization
Heart Failure
Stroke
Hemorrhage
Therapeutics

Keywords

  • Antiarrhythmic drug
  • Atrial fibrillation
  • Outcome
  • Rhythm control

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Impact of drug alteration to maintain rhythm control in paroxysmal Atrial fibrillation : Subanalysis From J-RHYTHM Study. / Endo, Ayaka; Kosaka, Shun; Suzuki, Shinya; Atarashi, Hirotsugu; Kamakura, Shiro; Sakurai, Masayuki; Nakaya, Haruaki; Fukatani, Masahiko; Mitamura, Hideo; Yamazaki, Tsutomu; Yamashita, Takeshi; Ogawa, Satoshi.

In: Circulation Journal, Vol. 74, No. 5, 2010, p. 870-875.

Research output: Contribution to journalArticle

Endo, A, Kosaka, S, Suzuki, S, Atarashi, H, Kamakura, S, Sakurai, M, Nakaya, H, Fukatani, M, Mitamura, H, Yamazaki, T, Yamashita, T & Ogawa, S 2010, 'Impact of drug alteration to maintain rhythm control in paroxysmal Atrial fibrillation: Subanalysis From J-RHYTHM Study', Circulation Journal, vol. 74, no. 5, pp. 870-875. https://doi.org/10.1253/circj.CJ-09-0643
Endo, Ayaka ; Kosaka, Shun ; Suzuki, Shinya ; Atarashi, Hirotsugu ; Kamakura, Shiro ; Sakurai, Masayuki ; Nakaya, Haruaki ; Fukatani, Masahiko ; Mitamura, Hideo ; Yamazaki, Tsutomu ; Yamashita, Takeshi ; Ogawa, Satoshi. / Impact of drug alteration to maintain rhythm control in paroxysmal Atrial fibrillation : Subanalysis From J-RHYTHM Study. In: Circulation Journal. 2010 ; Vol. 74, No. 5. pp. 870-875.
@article{0770039626914c92b677680fa2b7cebc,
title = "Impact of drug alteration to maintain rhythm control in paroxysmal Atrial fibrillation: Subanalysis From J-RHYTHM Study",
abstract = "Background: The Japanese Rhythm Management Trial for Atrial Fibrillation (J-RHYTHM) study showed rhythm control was associated with fewer changes in the assigned treatment strategy compared to rate control in atrial fibrillation (AF). The aim was to describe how antiarrhythmics (AAs) were altered in the rhythm control arm and whether altering AAs would impact long-term outcomes. Methods and Results: Of 390 enrolled patients, 23.5{\%} altered their AAs (drug alteration [DA] group). The hard endpoint (HE) was defined as a composite of death, stroke, embolism, major bleeding or heart failure hospitalization; soft endpoint (SE) was defined physical/psychological disability requiring alteration of treatment strategy. The patients were followed for 1.7 years. No significant difference was noted in the occurrence of HE (4.0{\%} vs 6.5{\%}, P=0.31), but DA-group patients had higher rates of SE (9.3{\%} vs 18.4{\%}, P=0.017) compared to single AA patients. The DA group was also associated with the occurrence of SE after adjustment (HR 1.90, P=0.042). When the DA group was subdivided according to the use of class III drugs or change of drugs between classes, there were no differences in outcomes. Conclusions: The need to change AA was associated with physical/psychological disabilities that seemed not to be relieved simply by changing AAs, and this should be considered as a marker for refractory paroxysmal AF requiring other strategies.",
keywords = "Antiarrhythmic drug, Atrial fibrillation, Outcome, Rhythm control",
author = "Ayaka Endo and Shun Kosaka and Shinya Suzuki and Hirotsugu Atarashi and Shiro Kamakura and Masayuki Sakurai and Haruaki Nakaya and Masahiko Fukatani and Hideo Mitamura and Tsutomu Yamazaki and Takeshi Yamashita and Satoshi Ogawa",
year = "2010",
doi = "10.1253/circj.CJ-09-0643",
language = "English",
volume = "74",
pages = "870--875",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "5",

}

TY - JOUR

T1 - Impact of drug alteration to maintain rhythm control in paroxysmal Atrial fibrillation

T2 - Subanalysis From J-RHYTHM Study

AU - Endo, Ayaka

AU - Kosaka, Shun

AU - Suzuki, Shinya

AU - Atarashi, Hirotsugu

AU - Kamakura, Shiro

AU - Sakurai, Masayuki

AU - Nakaya, Haruaki

AU - Fukatani, Masahiko

AU - Mitamura, Hideo

AU - Yamazaki, Tsutomu

AU - Yamashita, Takeshi

AU - Ogawa, Satoshi

PY - 2010

Y1 - 2010

N2 - Background: The Japanese Rhythm Management Trial for Atrial Fibrillation (J-RHYTHM) study showed rhythm control was associated with fewer changes in the assigned treatment strategy compared to rate control in atrial fibrillation (AF). The aim was to describe how antiarrhythmics (AAs) were altered in the rhythm control arm and whether altering AAs would impact long-term outcomes. Methods and Results: Of 390 enrolled patients, 23.5% altered their AAs (drug alteration [DA] group). The hard endpoint (HE) was defined as a composite of death, stroke, embolism, major bleeding or heart failure hospitalization; soft endpoint (SE) was defined physical/psychological disability requiring alteration of treatment strategy. The patients were followed for 1.7 years. No significant difference was noted in the occurrence of HE (4.0% vs 6.5%, P=0.31), but DA-group patients had higher rates of SE (9.3% vs 18.4%, P=0.017) compared to single AA patients. The DA group was also associated with the occurrence of SE after adjustment (HR 1.90, P=0.042). When the DA group was subdivided according to the use of class III drugs or change of drugs between classes, there were no differences in outcomes. Conclusions: The need to change AA was associated with physical/psychological disabilities that seemed not to be relieved simply by changing AAs, and this should be considered as a marker for refractory paroxysmal AF requiring other strategies.

AB - Background: The Japanese Rhythm Management Trial for Atrial Fibrillation (J-RHYTHM) study showed rhythm control was associated with fewer changes in the assigned treatment strategy compared to rate control in atrial fibrillation (AF). The aim was to describe how antiarrhythmics (AAs) were altered in the rhythm control arm and whether altering AAs would impact long-term outcomes. Methods and Results: Of 390 enrolled patients, 23.5% altered their AAs (drug alteration [DA] group). The hard endpoint (HE) was defined as a composite of death, stroke, embolism, major bleeding or heart failure hospitalization; soft endpoint (SE) was defined physical/psychological disability requiring alteration of treatment strategy. The patients were followed for 1.7 years. No significant difference was noted in the occurrence of HE (4.0% vs 6.5%, P=0.31), but DA-group patients had higher rates of SE (9.3% vs 18.4%, P=0.017) compared to single AA patients. The DA group was also associated with the occurrence of SE after adjustment (HR 1.90, P=0.042). When the DA group was subdivided according to the use of class III drugs or change of drugs between classes, there were no differences in outcomes. Conclusions: The need to change AA was associated with physical/psychological disabilities that seemed not to be relieved simply by changing AAs, and this should be considered as a marker for refractory paroxysmal AF requiring other strategies.

KW - Antiarrhythmic drug

KW - Atrial fibrillation

KW - Outcome

KW - Rhythm control

UR - http://www.scopus.com/inward/record.url?scp=77951708270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951708270&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-09-0643

DO - 10.1253/circj.CJ-09-0643

M3 - Article

VL - 74

SP - 870

EP - 875

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 5

ER -